+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Adalimumab"

TNF Alpha Inhibitors Market Report 2026 - Product Thumbnail Image

TNF Alpha Inhibitors Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Market Report 2026 - Product Thumbnail Image

Biosimilar Monoclonal Antibodies Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Tumor Necrosis Factor Inhibitor Drugs Market Report 2026 - Product Thumbnail Image

Tumor Necrosis Factor Inhibitor Drugs Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Humira Drug Market Report 2026 - Product Thumbnail Image

Humira Drug Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
Ankylosing Spondylitis Market Report 2026 - Product Thumbnail Image

Ankylosing Spondylitis Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Ocular Immunosuppressants Market - Global Forecast 2026-2032 - Product Thumbnail Image

Ocular Immunosuppressants Market - Global Forecast 2026-2032

  • Report
  • January 2026
  • 180 Pages
  • Global
From
Anti-Inflammatory Drugs - Global Strategic Business Report - Product Thumbnail Image

Anti-Inflammatory Drugs - Global Strategic Business Report

  • Report
  • April 2026
  • 488 Pages
  • Global
From
Autoimmune Drugs - Global Strategic Business Report - Product Thumbnail Image

Autoimmune Drugs - Global Strategic Business Report

  • Report
  • April 2026
  • 287 Pages
  • Global
From
Ankylosing Spondylitis - Global Strategic Business Report - Product Thumbnail Image

Ankylosing Spondylitis - Global Strategic Business Report

  • Report
  • April 2026
  • 271 Pages
  • Global
From
From
Uveitis Drugs - Global Strategic Business Report - Product Thumbnail Image

Uveitis Drugs - Global Strategic Business Report

  • Report
  • April 2026
  • 413 Pages
  • Global
From
From
Rheumatology Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Rheumatology Therapeutics - Global Strategic Business Report

  • Report
  • April 2026
  • 196 Pages
  • Global
From
From
Autoimmune Monoclonal Antibody Market Report 2026 - Product Thumbnail Image

Autoimmune Monoclonal Antibody Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Psoriasis Market Report 2026 - Product Thumbnail Image

Psoriasis Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
From
From
Loading Indicator

Adalimumab is a biologic drug used to treat a variety of immune disorders, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and juvenile idiopathic arthritis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Adalimumab is administered by subcutaneous injection and is available in both brand-name and generic forms. Adalimumab is one of the most widely prescribed drugs for immune disorders, and it has been approved for use in more than 100 countries. It is a highly effective treatment for many of the conditions it is used to treat, and it has been shown to improve quality of life for patients. Some of the companies in the Adalimumab market include AbbVie, Amgen, Biogen, Boehringer Ingelheim, Janssen Biotech, Merck, and Pfizer. Show Less Read more